Barclays lowered the firm’s price target on Elevance Health (ELV) to $501 from $622 and keeps an Overweight rating on the shares. The firm says that following a “chaotic first week” of Q3 earnings that featured material medical loss ratio misses and negative outlook surprises, it evaluated the resets and read-throughs from UnitedHealth’s and Elevance Health’s earnings reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $484 from $589 at TD Cowen
- Elevance Health price target lowered to $478 from $585 at RBC Capital
- Elevance Health cut to Hold at Argus on earnings pressure in 2024-2025
- Elevance Health price target lowered to $520 from $620 at Truist
- Elevance Health downgraded to Hold from Buy at Argus